Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06284317
Title	A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)
Acronym	ADOPT-lung
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	ETOP IBCSG Partners Foundation
Indications	lung non-small cell carcinoma
Therapies	Durvalumab
Age Groups:	adult \| senior
Covered Countries	NLD \| ITA \| IRL \| GBR \| FRA \| EST \| CHE \| BEL \| AUT \| AUS